AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10347354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth surface morphology (anatomically grooved vs ungrooved)
Number of subjects: 48
Study 7493435 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycaemia (2.5 mmol/l)
Number of subjects: 10
Study 7493435 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycaemia
Number of subjects: 10
Study 7493435 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of antecedent hypoglycaemia for 6 days
Number of subjects: 10
Study 1974493 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine, 40 mg after the evening meal for 28 days
Number of subjects: 3
Study 1974493 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine, 300 mg four times a day for seven days followed by 300 mg at night until day 28
Number of subjects: 3
Study 1974493 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine, 300 mg three times a day
Number of subjects: 3
Study 1974493 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine, 300 mg at night
Number of subjects: 3
Study 6244414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical neomycin/polymyxin-B
Number of subjects: 64
Study 6244414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose daily macrocrystals of nitrofurantoin
Number of subjects: 64
Study 6244414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical treatment and oral nitrofurantoin
Number of subjects: 64
Study 6244414 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 64
Study 31098989 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem–vaborbactam (MV)
Number of subjects: 0
Study 31098989 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 0
Study 28807739 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-enhanced Diabetes Prevention Program (DPP)
Number of subjects: 221
Study 28807739 — intervention group
Group type: COMPARATOR
Intervention: Standard Diabetes Prevention Program (DPP)
Number of subjects: 221
Study 25991758 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolised algorithm using stroke volume variation to guide fluid administration
Number of subjects: 144
Study 25991758 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 144
Study 25991758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 23471488 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pellets (5 g, 47% lauric acid by weight)
Number of subjects: 8
Study 23471488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21452269 — intervention group
Group type: EXPERIMENTAL
Intervention: Wegener's Granulomatosis Etanercept Trial (WGET) cohort
Number of subjects: 535
Study 21452269 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 535
Study 21452269 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic hypertension
Number of subjects: 535
Study 21452269 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive proteinase 3 (PR3) ANCA status
Number of subjects: 535
Study 21452269 — intervention group
Group type: COMPARATOR
Intervention: EUVAS trials
Number of subjects: 535
Study 19351658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 350 microg 17beta-estradiol + 550 microg norethisterone
Number of subjects: 1741
Study 19351658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 350 microg 17beta-estradiol + 50 or 175 microg norethisterone
Number of subjects: 1741
Study 19351658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal regimens
Number of subjects: 1741
Study 19351658 — intervention group
Group type: COMPARATOR
Intervention: Oral 2 mg 17beta-estradiol + 1 mg norethisterone
Number of subjects: 1741
Study 18006769 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐510 10 mg twice daily
Number of subjects: 0
Study 18006769 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐510 100 mg twice daily
Number of subjects: 0
Study 18006769 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14602190 — intervention group
Group type: EXPERIMENTAL
Intervention: GL (Gelucire 44/14 and Labrasol)
Number of subjects: 8
Study 14602190 — intervention group
Group type: COMPARATOR
Intervention: CD (piroxicam:beta‐cyclodextrin complex)
Number of subjects: 8
Study 14602190 — intervention group
Group type: COMPARATOR
Intervention: PP (pure piroxicam)
Number of subjects: 8
Study 10872552 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade
Number of subjects: 596
Study 10872552 — intervention group
Group type: COMPARATOR
Intervention: hypertensive patients
Number of subjects: 596
Study 10872552 — intervention group
Group type: COMPARATOR
Intervention: normotensive controls
Number of subjects: 596
Study 9359726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil for 10 days
Number of subjects: 100
Study 9359726 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor for 10 days
Number of subjects: 100
Study 8491498 — intervention group
Group type: EXPERIMENTAL
Intervention: Random zero sphygmomanometer
Number of subjects: 1356
Study 3897451 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study 3897451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 0
Study 3897451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3897451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemagglutination inhibition (HAI)
Number of subjects: 0
Study 3897451 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement fixation (CF)
Number of subjects: 0
Study 3897451 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralization
Number of subjects: 0
Study 3897451 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 0
Study 31875661 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Determination method
Number of subjects: 10
Study 30378311 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs plus Traditional Chinese Medicine (TCM)
Number of subjects: 59
Study 30378311 — intervention group
Group type: COMPARATOR
Intervention: EGFR-TKIs
Number of subjects: 59
Study 26944733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice a day (D150)
Number of subjects: 0
Study 26944733 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran 110 mg twice a day (D110)
Number of subjects: 0
Study 24189245 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1322322 (1,500 mg, twice daily intravenous dosing for 4 days)
Number of subjects: 0
Study 21712704 — intervention group
Group type: EXPERIMENTAL
Intervention: GSUC (sealed gauze dressing)
Number of subjects: 87
Study 21712704 — intervention group
Group type: COMPARATOR
Intervention: VAC (vacuum-assisted closure device)
Number of subjects: 87
Study 20229001 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (group F)
Number of subjects: 40
Study 20229001 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (group R)
Number of subjects: 40
Study 18387026 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention curriculum implementation
Number of subjects: 62
Study 18387026 — intervention group
Group type: EXPERIMENTAL
Intervention: Year long class schedule
Number of subjects: 62
Study 18387026 — intervention group
Group type: EXPERIMENTAL
Intervention: High teacher self-efficacy
Number of subjects: 62
Study 18387026 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived curriculum complexity
Number of subjects: 62
Study 16165400 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 mg twice daily for 9 days
Number of subjects: 17
Study 16165400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12865102 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol (2.5 mg)
Number of subjects: 27
Study 12865102 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (10 mg)
Number of subjects: 27
Study 12865102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nebulized saline)
Number of subjects: 27
Study 10805059 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline treatment
Number of subjects: 17
Study 10805059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8644690 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g FOS/d
Number of subjects: 12
Study 8644690 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 12
Study 2004542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide oral suspension, 5 mg/kg/day divided into 3 daily doses for 5 days
Number of subjects: 42
Study 2004542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6440445 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 9
Study 6440445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbitone (100 mg)
Number of subjects: 9
Study 6440445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30873696 — intervention group
Group type: COMPARATOR
Intervention: PFMX (control group)
Number of subjects: 37
Study 30873696 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMX plus Pfilates and Hypopressives (APFX)
Number of subjects: 37
Study 29774477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g q8h for adults and 50 mg/kg q8h for children)
Number of subjects: 175
Study 29774477 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone/sulbactam plus amikacin (CS + A) (2 g q8h for adults and 50 mg/kg q8h for children plus amikacin 15 mg/kg once a day)
Number of subjects: 175
Study 29774477 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone/sulbactam plus amikacin (CS + A)
Number of subjects: 175
Study 27605407 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable emulsion (E1)
Number of subjects: 21
Study 27605407 — intervention group
Group type: COMPARATOR
Intervention: Unstable emulsion (E4)
Number of subjects: 21
Study 23901043 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks plus intranasal budesonide for 12 weeks
Number of subjects: 89
Study 23901043 — intervention group
Group type: COMPARATOR
Intervention: No steroid treatment (Control)
Number of subjects: 89
Study 22083515 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Pelvic Organ Prolapse Quantification (POP-Q) system
Number of subjects: 511
Study 22083515 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted kappa statistic
Number of subjects: 511
Study 20409751 — intervention group
Group type: COMPARATOR
Intervention: D1 lymphadenectomy
Number of subjects: 711
Study 20409751 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 711
Study 18310867 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics immediately following surgery and for at least seven days thereafter (Group-1)
Number of subjects: 100
Study 18310867 — intervention group
Group type: COMPARATOR
Intervention: One gram of cephazoline injected intravenously before anesthesia and continued for 24 hours after surgery (Group-2)
Number of subjects: 100
Study 16085556 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily serum C-reactive protein (CRP) levels measured during the 3 week period following treatment
Number of subjects: 104
Study 16085556 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels cut-off point of 100 mg/l
Number of subjects: 104
Study 16085556 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP velocity cut-off point of 15 mg/l/day
Number of subjects: 104
Study 11818372 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive-addition lenses
Number of subjects: 469
Study 11818372 — intervention group
Group type: COMPARATOR
Intervention: Single-vision lenses
Number of subjects: 469
Study 10068969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (1 mg W kg‐1)
Number of subjects: 91
Study 10068969 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (1 mg W kg‐1)
Number of subjects: 91
Study 10068969 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 ml W kg‐1)
Number of subjects: 91
Study 8657963 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry boldo extract (2.5 g)
Number of subjects: 12
Study 8657963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 12
Study 1646369 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment for 9 months
Number of subjects: 19
Study 1646369 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated PTH-NANB patients)
Number of subjects: 19
Study 6271838 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 52
Study 6271838 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 52
Study 30765762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Yijing Fang (BSYJF) with calcium carbonate 300 mg daily
Number of subjects: 140
Study 30765762 — intervention group
Group type: COMPARATOR
Intervention: Placebo with calcium carbonate 300 mg daily
Number of subjects: 140
Study 27858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination by raters A, B, C, and D
Number of subjects: 100
Study 27858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination parameters
Number of subjects: 100
Study 27858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop test positive
Number of subjects: 100
Study 27858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital interspinous pressure test positive
Number of subjects: 100
Study 27858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled parameters of physical examination suggestive of SI joint pain
Number of subjects: 100
Study 27858686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled parameters of physical examination suggestive of facet joint or disc pain
Number of subjects: 100
Study 25742535 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (behavioral lifestyle intervention program)
Number of subjects: 0
Study 25742535 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group (no immediate intervention)
Number of subjects: 0
Study 23538757 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 37ºC
Number of subjects: 80
Study 23538757 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at 25ºC
Number of subjects: 80
Study 23538757 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage medium in distilled water
Number of subjects: 80
Study 23538757 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage medium dry
Number of subjects: 80
Study 23538757 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimen dimensions 10×2×2 mm
Number of subjects: 80
Study 23538757 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimen dimensions 25×2×2 mm
Number of subjects: 80
Study 21550158 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel applied to the socket of the third molar
Number of subjects: 60
Study 21550158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 60
Study 19117316 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy (four-dose intralesional injection series at eight-week intervals)
Number of subjects: 182
Study 19117316 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy (for macrocystic LM)
Number of subjects: 182
Study 19117316 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy (for mixed macrocystic-microcystic LM)
Number of subjects: 182
Study 19117316 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy (for microcystic LM)
Number of subjects: 182
Study 19117316 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (observational controls)
Number of subjects: 182
Study 19117316 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 immunotherapy
Number of subjects: 182
Study 19117316 — intervention group
Group type: COMPARATOR
Intervention: OK-432 immunotherapy vs historical surgical data on LM
Number of subjects: 182
Study 17826452 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure education program
Number of subjects: 62
Study 17826452 — intervention group
Group type: COMPARATOR
Intervention: Control group (home visits)
Number of subjects: 62
Study 15100340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 818
Study 15100340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study 11740145 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (500 IU/week if <2 years or 1,000 IU/week if >2 years for 6 weeks)
Number of subjects: 155
Study 11740145 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG + hMG (hCG as in group 1 + hMG 75 IU/week for 6 weeks)
Number of subjects: 155
Study 11740145 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (1,200 microg/daily for 28 days)
Number of subjects: 155
Study 11740145 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH + hCG (1,200 microg/daily for 28 days + 1,500 IU/week for 3 weeks)
Number of subjects: 155
Study 11740145 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 155
Study 10707784 — intervention group
Group type: EXPERIMENTAL
Intervention: t(14;18) translocation detection in healthy individuals
Number of subjects: 264
Study 10707784 — intervention group
Group type: COMPARATOR
Intervention: t(14;18) translocation detection in family members of NHL patients
Number of subjects: 264
Study 9174522 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist guards
Number of subjects: 2
Study 9174522 — intervention group
Group type: COMPARATOR
Intervention: No wrist guards (control)
Number of subjects: 2
Study 1487229 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g propacetamol HCl given intravenously over a 15‐min period
Number of subjects: 12
Study 1487229 — intervention group
Group type: COMPARATOR
Intervention: 500 mg paracetamol given orally
Number of subjects: 12
Study 1487229 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g propacetamol HCl given as a 15‐min infusion
Number of subjects: 12
Study 1487229 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g propacetamol HCl given as a 2‐min bolus injection
Number of subjects: 12
Study 2987102 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire tumor or ten blocks examined in a blinded and randomized fashion using the revised (1981) WHO classification
Number of subjects: 100
Study 30854571 — intervention group
Group type: EXPERIMENTAL
Intervention: Light blue gel nail polish using Masimo oximeter
Number of subjects: 17
Study 30854571 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange gel nail polish using Masimo oximeter
Number of subjects: 17
Study 30854571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink gel nail polish using Philips oximeter
Number of subjects: 17
Study 30854571 — intervention group
Group type: EXPERIMENTAL
Intervention: Black gel nail polish using Philips oximeter
Number of subjects: 17
Study 30327407 — intervention group
Group type: EXPERIMENTAL
Intervention: Namaste Care Family programme
Number of subjects: 0
Study 27271828 — intervention group
Group type: EXPERIMENTAL
Intervention: Authors' physical rehabilitation program
Number of subjects: 60
Study 27271828 — intervention group
Group type: COMPARATOR
Intervention: Control group rehabilitation program (recommended scheme)
Number of subjects: 60
Study 24932893 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message plus call
Number of subjects: 242
Study 24932893 — intervention group
Group type: EXPERIMENTAL
Intervention: Call
Number of subjects: 242
Study 24932893 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message
Number of subjects: 242
Study 24932893 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 242
Study 22699097 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-use therapy (FUT) program, constraint of the unaffected hand for 6 hours per day, duration of 2 weeks
Number of subjects: 23
Study 22699097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 23
Study 22699097 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-use therapy (FUT) program
Number of subjects: 23
Study 20115970 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure dressing (NPD)
Number of subjects: 54
Study 20115970 — intervention group
Group type: COMPARATOR
Intervention: Static pressure dressing (SPD)
Number of subjects: 54
Study 18797097 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 89
Study 18797097 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) + alpha-tocopherol (AT)
Number of subjects: 89
Study 18797097 — intervention group
Group type: COMPARATOR
Intervention: Control group (OCC patients)
Number of subjects: 89
Study 16418113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sensory stimulation (experimental group)
Number of subjects: 26
Study 16418113 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 26
Study 16418113 — intervention group
Group type: COMPARATOR
Intervention: Healthy, full-term males
Number of subjects: 26
Study 16418113 — intervention group
Group type: COMPARATOR
Intervention: Healthy, full-term females
Number of subjects: 26
Study 11836286 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily for 3 months, followed by 20 mg daily for 3 months)
Number of subjects: 80
Study 11836286 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg and 20 mg)
Number of subjects: 80
Study 11836286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10094169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg b.i.d. IV/IM initially, decreasing over 40 days) with antituberculosis treatment
Number of subjects: 178
Study 10094169 — intervention group
Group type: COMPARATOR
Intervention: Control group (antituberculosis treatment only)
Number of subjects: 178
Study 7593627 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methacholine (increasing concentrations); no deep inspirations allowed
Number of subjects: 20
Study 7593627 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methacholine (increasing concentrations); deep inspirations initiated
Number of subjects: 20
Study 7593627 — intervention group
Group type: COMPARATOR
Intervention: Forced expirations from a normal end‐tidal inspiration
Number of subjects: 20